Orgaran during rotational atherectomy in the setting of heparin‐induced thrombocytopenia

Hale, L. Paulette; Smith, Karen; Braden, Gregory A.; Owen, John

doi:10.1002/(sici)1097-0304(199811)45:3<318::aid-ccd23>3.3.co;2-u

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 1 case study that reported on the use of danaparoid for a patient with remote HIT requiring PCI. 110 This study reported on the outcomes of thrombotic and bleeding events. Two studies reported indirect evidence of treatment with non-heparin anticoagulants during PCI among patients without HIT.…”

Section: Percutaneous Cardiovascular Interventionmentioning

confidence: 99%

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

et al. 2018

View full text Add to dashboard Cite

Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about diagnosis and management of HIT. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 33 recommendations. The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percutaneous cardiovascular intervention, renal replacement therapy, and venous thromboembolism prophylaxis. Conclusions: Strong recommendations include use of the 4Ts score rather than a gestalt approach for estimating the pretest probability of HIT and avoidance of HIT laboratory testing and empiric treatment of HIT in patients with a low-probability 4Ts score. Conditional recommendations include the choice among non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, fondaparinux, direct oral anticoagulants) for treatment of acute HIT.

show abstract

Section: Percutaneous Cardiovascular Interventionmentioning

confidence: 99%

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Danaparoid has also been used to provide antithrombotic therapy during cardiac catheterization, with or without stenting or other maneuvers, 95 with anecdotal reports of success. 173,174 Recommendations regarding use of alternative anticoagulants in PCI also are given in the Chapter in this Supplement by Popma et al…”

Section: Pcismentioning

confidence: 99%

Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention

Warkentin¹,

Greinacher²

2004

Chest

731

219

View full text Add to dashboard Cite

“…Case reports demonstrated the successful use of danaparoid in combination with abciximab during PCI [130] and rotational atherectomy [131] when heparin was contraindicated. Whereas new alternative coagulants like argatroban and bivalirudin have been evaluated extensively in the setting of PCI and particularly in patients with HIT, the safety and efficacy of danaparoid in patients with HIT undergoing PCI has not been assessed in large scale trials so far.…”

Section: Factor Xa Inhibitors Danaparoidmentioning

confidence: 99%

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Joost

Kurowski²,

Radke³

2008

CPD

View full text Add to dashboard Cite

The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced thrombocytopenia (HIT) is expected to range between 0.1 and 5%, the application of an appropriate anticoagulant agent has become a mandatory issue. This review will provide current pathophysiological insights of HIT as well as contemporary alternative anticoagulant strategies during PCI in patients with or at risk of HIT.

show abstract

Orgaran during rotational atherectomy in the setting of heparin‐induced thrombocytopenia

Cited by 5 publications

References 0 publications

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Contact Info

Product

Resources

About